1591P - Gastric cancer in young patients under 40 years: 5-year analyses of Georgian cancer registry

Background

Gastric cancer (GC) is 5th most common cancer and 4th most common cause of cancer death worldwide. The rate of GC in patients < 40 years in different countries is ∼ 5%. The incidence and characteristics of GC in <40 patients were not studied in Georgian population. We analyzed clinicopathologic features of early onset GC in Georgia.

Methods

In this study we analyzed data from national cancer registry of Georgia 2015-2021. The data included number of cases, age, sex, anatomic location, stage, pathology and treatment types of GC. Aim of the study was to investigate clinicopathologic characteristics, treatment approaches and survival rates of GC in patients <40 compared to entire cohort. Survival was summarized by Kaplan-Meier method.

Results

A total of 1775 patients with GC were included in the study during 2015-2021. Out of 1775 patients 52 (2,9%) were < 40 years. Median age 34 (17-39). In <40 patients 50% were female, while in entire cohort 62% were male. No differences were seen in anatomic location, tumor grade, stage. Stage III (25 % in <40 patients vs 29% in entire cohort) and IV (40% vs 43%) were most common. Differences were seen in pathologic types - not otherwise classified adenocarcinoma 31% in <40 patients vs 25% in entire cohort (P value 0.3367), not otherwise classified carcinoma 26 % vs 2% (P value <0.0001), signet ring carcinoma 17% vs 6% respectively (P value 0.0004). In entire cohort rate of undifferentiated carcinoma was 30% and tubular adenocarcinoma 16%, which were not seen in <40 patients. 23% of <40 patients vs 30% entire cohort had surgery (P value 0.2294) and 42% vs 30% chemotherapy (P value 0.0714). Median overal survival (OS) for patients <40 was 20 months (95% CI 9,0-30,0) and 13 months for entire cohort (95% CI 12,0-15,0) (p value – 0,1488).

Conclusions

This study showed, that in Georgian <40 patients GC is equally distributed between both sexes, while in the entire cohort it is slighlty more common in males. Pathologic types as not otherwise classified carcinoma and signet ring carcinoma were seen most frequently in <40 patients. <40 patients were slightly more likely to receive chemotherapy and surgery. However, median OS was <2 years for patients <40. Further studies are required to understand causes of early onset GC in Georgian patients and to improve survival.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

T. Esakia.

Funding

Has not received any funding.

Disclosure

E. Smyth: Financial Interests, Personal, Invited Speaker: Amgen, Bristol Myers Squibb, Imedex, Merck, Novartis, Prova Education, Servier, TouchIME, Elsevier, PeerVoice, Cor2Ed, Daiichi Sankyo; Financial Interests, Personal, Other, TSC: Amgen; Financial Interests, Personal, Advisory Board: Astellas, AstraZeneca, Bristol Myers Squibb, Bristol Myers Squibb, My Personal Therapeutics, Novartis, Roche, Servier, Zymeworks, Viracta; Financial Interests, Personal, Other, IDMC: BeiGene, Zymeworks; Financial Interests, Personal, Other, IDMC chair: Everest Clinical Research; Financial Interests, Personal, Officer: EORTC GI Clinical Trials Group; Financial Interests, Institutional, Local PI: Daiichi Sankyo, Merus, Basilea, MSD, Mirati; Financial Interests, Institutional, Coordinating PI: Roche, AstraZeneca, Amgen; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb; Non-Financial Interests, Leadership Role, Trustee: UK & Ireland Oesophagogastric Group (UKIOG). All other authors have declared no conflicts of interest.